SBIR/STTR Research Award

EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.

Award identifier fced354d2b0a49a3f7d27726fb33966d4624356c0e70757737084b2d63c5c807Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$600,000

Program and phase

SBIR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SILVER LAKE RESEARCH CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
C9FZMJCTQFP4
Solicitation number
Not reported
Topic code
83

Research abstract

The investigation of infectious disease mechanisms, treatments, and vaccines relies on animal models. Non-traditional animal models – such as the guinea pig model of tuberculosis - suffer from a lack of reagents, notably monoclonal antibodies (MAbs), used for characterizing subsets of immune cells and the cytokines they produce. For the guinea pig, a list of 25 high-priority targets has been compiled by leading investigators in tuberculosis vaccinology – cell surface markers of immune cells and cytokines for which current MAb tools are inadequate or nonexistent. The production of such phenotyping antibodies through traditional methods is laborious, time-consuming, and expensive.In this project, we will use the EAP Immunization System to produce needed MAbs for characterizing immune responses of the guinea pig. The EAP System uses small synthetic peptides for the induction and preliminary characterization of new antibodies. This methodology has been used by SLRC to produce hundreds of MAbs for targets that were previously inaccessible, including ongoing parallel work for the guinea pig animal model. In Phase I of this project, we will address six targets; the remainder will be addressed in Phase II. At the successful conclusion of this project, new reagents will be available to significantly enhance research capabilities for tuberculosis and other diseases.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

12 SBIR/STTR records share this UEI (2006–2023). Reported award amounts total $9,165,947. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Environmental Protection Agency

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.